Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Dec 30;8(12):e86059.
doi: 10.1371/journal.pone.0086059. eCollection 2013.

Neuromuscular electrical stimulation of the quadriceps in patients with non-small cell lung cancer receiving palliative chemotherapy: a randomized phase II study

Matthew Maddocks  1 , Vanessa Halliday  2 , Alpna Chauhan  3 , Victoria Taylor  4 , Annmarie Nelson  5 , Cathy Sampson  5 , Anthony Byrne  5 , Gareth Griffiths  5 , Andrew Wilcock  4
Affiliations
Clinical Trial

Neuromuscular electrical stimulation of the quadriceps in patients with non-small cell lung cancer receiving palliative chemotherapy: a randomized phase II study

Matthew Maddocks et al. PLoS One. .

Abstract

Background: A reduced exercise capacity is associated with increased morbidity and mortality in patients with advanced non-small cell lung cancer (NSCLC). Therapeutic exercise can be beneficial and neuromuscular electrical stimulation (NMES) of the quadriceps muscles may represent a practical approach. The primary aim of this study was to determine the acceptability of NMES of the quadriceps to patients with NSCLC used alongside palliative chemotherapy. Secondary aims explored aspects of safety and efficacy of NMES in this setting.

Methods: Patients with advanced NSCLC due to receive first-line palliative chemotherapy were randomized to usual care with or without NMES. They were asked to undertake 30 minute sessions of NMES, ideally daily, but as a minimum, three times weekly. For NMES to be considered acceptable, it was predetermined that ≥80% of patients should achieve this minimum level of adherence. Qualitative interviews were held with a subset of patients to explore factors influencing adherence. Safety was assessed according to the Common Terminology Criteria for Adverse Events. Quadriceps muscle strength, thigh lean mass, and physical activity level were assessed at baseline and after three cycles of chemotherapy.

Results: 49 patients (28 male, median (IQR) age 69 (64-75) years) participated. Of 30 randomized to NMES, 18 were eligible for the primary endpoint, of whom 9 (50% [90% CI, 29 to 71]) met the minimum level of adherence. Adherence was enhanced by incorporating sessions into a daily routine and hindered by undesirable effects of chemotherapy. There were no serious adverse events related to NMES, nor significant differences in quadriceps muscle strength, thigh lean mass or physical activity level between groups.

Conclusions: NMES is not acceptable in this setting, nor was there a suggestion of benefit. The need remains to explore NMES in patients with cancer in other settings.

Trial registration: Current Controlled Trials ISRCTN 42944026 www.controlled-trials.com/ISRCTN42944026.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Study flow diagram
See this image and copyright information in PMC

References

    1. Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR (2009) Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol 10: 598-605. doi: 10.1016/S1470-2045(09)70031-2. PubMed: 19482248. - DOI - PubMed
    1. Jones LW, Watson D, Harndon JE, Eves ND, Haithcock BE et al. (2012) Peak oxygen consumption and long-term all-cause mortality in non-small cell lung cancer. Cancer 116: 4825-4832. - PMC - PubMed
    1. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS et al. (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87: 264-267. doi: 10.1038/sj.bjc.6600466. PubMed: 12177792. - DOI - PMC - PubMed
    1. Jones LW, Eves ND, Mackey JR, Peddle CJ, Haykowsky M et al. (2008) Systemic inflammation, cardiorespiratory fitness, and quality of life in patients with advanced non-small cell lung cancer. J Thorac Oncol 3: 194-195. doi: 10.1097/JTO.0b013e318160f36b. PubMed: 18303444. - DOI - PubMed
    1. Kasymjanova G, Correa JA, Kreisman H, Dajczman E, Pepe C et al. (2009) Prognostic value of the six minute walk in advanced non-small cell lung cancer. J Thorac Oncol 4: 602-607. doi: 10.1097/JTO.0b013e31819e77e8. PubMed: 19276833. - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data